ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals (ORMP) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating stable recent operational conditions. However, low signal in our 90-day window does not mean low risk; the company operates in the competitive biotech sector where capital structure and pipeline execution drive shareholder outcomes. The full $49 Report extends analysis to 12 months of filing history, calculates dilution risk scores based on equity issuance patterns, maps financing history and runway, and identifies AI-detected risk signals that early-stage warnings may not yet surface. The full $49 Report adds quantified dilution trajectory, 8-K context across a full fiscal year, and predictive risk signals built from comprehensive SEC data.